[1]徐永康,付舒敏,李　丹,等.肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展[J].介入放射学杂志,2023,32(01):94-97.
　XU Yongkang,FU Shumin,LI Dan,et al.Research progress in hepatic arterial infusion chemotherapy combined with systemic therapy for the treatment of primary hepatocellular carcinoma[J].journal interventional radiology,2023,32(01):94-97.
点击复制

肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年01
页码:
94-97
栏目:
综述
出版日期:
2023-02-13

文章信息/Info

Title:
Research progress in hepatic arterial infusion chemotherapy combined with systemic therapy for the treatment of primary hepatocellular carcinoma
作者:
徐永康; 　付舒敏; 　李　丹; 　毛　野; 　吴建兵
Author(s):
XU Yongkang;  FU Shumin;  LI Dan;  MAO Ye;  WU Jianbing.
Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province 330006, China
关键词:
【关键词】原发性肝癌; 肝动脉灌注化疗; 分子靶向治疗; 免疫治疗
文献标志码:
A
摘要:
【摘要】　原发性肝癌是常见的恶性肿瘤之一，肝动脉灌注化疗（HAIC）和系统治疗是中晚期肝癌主要的治疗方式。HAIC通过方案及介入技术的改进，能够有效控制肝内病灶且安全性好。系统治疗从单一的靶向药物或免疫治疗进入靶免联合的时代，治疗手段日益丰富。但无论是HAIC或系统治疗，单一治疗效果有限。近年来，HAIC联合系统治疗能有效提高客观缓解率、延长无进展生存时间、增加转化切除机会。但对于长期生存获益、选择最优联合方案、筛选合适的目标人群等问题的解决仍需积累临床经验。当前证据表明，HAIC联合索拉非尼对于肝癌合并门静脉主干癌栓疗效确切，联合仑伐替尼或免疫治疗仍需探索，联合免疫及靶向治疗是未来一线治疗的潜在选择。

参考文献/References:

［1］　Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71: 209-249.
［2］　Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66: 115-132.
［3］ Vogel A, Martinelli E, ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma （HCC） from the ESMO clinical practice guidelines［J］. Ann Oncol, 2021, 32: 801-805.
［4］ Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update［J］. Liver Cancer, 2021, 10: 181- 223.
［5］ Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases［J］. Hepatology, 2018, 68: 723-750.
［6］ European Association for the Study of the Liver . EASL clinical practice guidelines: management of hepatocellular carcinoma［J］. J Hepatol, 2018, 69: 182-236.
［7］ Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma Nature reviews［J］. Dis Primers, 2021, 7: 6.
［8］　赵东旭，张　磊，姜小庆，等. HAIC是老技术还是新方法——理性看待肝动脉灌注化疗［J］. 介入放射学杂志，2022，31：2-8.
［9］ Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med, 2008, 359: 378-390.
［10］ Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial［J］. Lancet Oncol, 2009, 10: 25–34.
［11］ Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase Ⅱ trial［J］. Ann Oncol, 2016, 27: 2090-2096.
［12］ Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma （SILIUS）: a randomised, open label, phase 3 trial［J］. Lancet Gastroenterol Hepatol, 2018, 3: 424-432.
［13］ Kondo M, Morimoto M, Kobayashi S, et al. Randomized, phase Ⅱ trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial［J］. BMC Cancer, 2019, 19: 954.
［14］ He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial［J］. JAMA Oncol, 2019, 5: 953-960.
［15］ Wang X, Zheng K, Cao G, et al. 984P Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma with major portal vein tumor thrombosis（Vp3/4）: a randomized phase Ⅱ trial［J］. Ann Oncol, 2020, 31: S689.
［16］ Kudo M, Finn RS, Qin SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial［J］. Lancet, 2018, 391: 1163-1173.
［17］ Mai Q, Mo Z, Shi F, et al. Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma［J］. J Clin Oncol, 2020, 38（15_suppl）:e16603.
［18］ Ikeda M, Yamashita T, Ogasawara S, et al. Multicenter phase Ⅱ trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD［J］. Ann Oncol, 2021, 32: S821-S822.
［19］ Rech AJ, Dada H, Kotzin JJ, et al. Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer［J］. Cancer Res, 2018, 78: 4282-4291.
［20］ Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma［J］. J Hepatol, 2017, 66: 545-551.
［21］ Vogel A, Saborowski A, Hinrichs J, et al. IMMUTACE: a biomarker- orientated, multi center phaseⅡAIO study of transarterial chemoembolization（TACE）in combination with nivolumab performed for intermediate stage hepatocellular carcinoma（HCC）［J］. Ann Oncol, 2021, 32: S1312.
［22］ Xu L, Zhang Y, Wang X, et al. Transarterial infusion chemotherapy （TAI） combined with sintilimab in locally advanced, potentially resectable hepatocellular carcinoma （HCC）［J］. J Clin Oncol,2020, 38（15_suppl）:e16593.
［23］ Mei J, Li SH, Li QJ, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma［J］. J Hepatocell Carcinoma, 2021, 8: 167-176.
［24］ Gu YK, Zhang TQ, Huang ZL, et al. Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma: real-world data from a single center［J］. J Clin Oncol, 2020, 38（15_suppl）:e16602.
［25］ He MK, Ming S, Lai Z, et al. A phaseⅡtrial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma （LTHAIC study）［J］. J Clin Oncol, 2021, 39（15_suppl）:4083.
［26］ Zhang TQ, Zuo MX, Geng Z J, et al. 946P Hepatic artery infusion chemotherapy （HAIC） combined with apatinib and camrelizumab for hepatocellular carcinoma （HCC） in BCLC stage C: a prospective, single-arm, phaseⅡtrial （TRIPLET study）［J］. Ann Oncol, 2021, 32: S825.
［27］ He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma［J］. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
［28］Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma［J］. Front Oncol, 2021, 11: 618206.
［29］陈敏山，胡自力. 肝动脉灌注化疗在肝癌转化治疗中的研究进展［J］. 中华消化外科杂志，2021，20：171-177．
［30］陈晓明，程永德. 中期肝癌TACE之争论与研究现状［J］. 介入放射学杂志，2021，30：751-755．
［31］ Xue J, Ni H, Wang F, et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy［J］. J Interv Med, 2021, 4: 105-113.

相似文献/References:

[1]李晓光,金征宇,潘杰,等.肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2010,(06):442.
　LI Xiaoguang,JIN Zhengyu,PAN Jie,et al.Hepatic transarterial chemoperfusion and chemoembolization for the treatment of liver metastases from pancreatic neuroendocrine tumors：a therapeutic analysis[J].journal interventional radiology,2010,(01):442.
[2]陈伟敏,罗佐权.肝癌肝动脉灌注化疗与静脉输注硫代硫酸钠的“双路”疗法18例报告[J].介入放射学杂志,1992,(01):26.
[3]牛树茂,徐元贞,赵殿有,等.肝动脉灌注化疗后引起带状疱疹样皮疹六例报告[J].介入放射学杂志,1994,(01):54.
[4]秦伟,巫北海.5-FUDR经肝动脉灌注致硬化性胆管炎[J].介入放射学杂志,1996,(01):59.
[5]徐中琪,刘晟,许贇,等.完全性胸腹腔内脏反位合并原发性肝癌行经皮微波消融治疗4例[J].介入放射学杂志,2016,(06):546.
　XU Zhong-qi,LIU Sheng,XU Yun,et al.Percutaneous microwave ablation for primary hepatocellular carcinoma in patients with thoracic and abdominal situs inversus totalis: report of 4 cases [J].journal interventional radiology,2016,(01):546.
[6]中国抗癌协会肿瘤介入学专业委员会,中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会.改良式经皮肝动脉化疗药盒植入技术中国专家共识（2022版）[J].介入放射学杂志,2022,31(07):633.
　Professional Committee of Oncology Intervention,China Anti-Cancer Association,Chinese expert consensus on the modified implantation technique of port-catheter system for percutaneous hepatic arterial infusion chemotherapy（version 2022）[J].journal interventional radiology,2022,31(01):633.
[7]曹莉明,张勇学,梁志会,等.载药微球栓塞治疗传统TACE抵抗的原发性肝癌临床疗效[J].介入放射学杂志,2023,32(01):59.
　CAO Liming,ZHANG Yongxue,LIANG Zhihui,et al.Drug-eluting beads-trancatheter arterial chemoembolization for the treatment of hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization: observation of its clinical effect[J].journal interventional radiology,2023,32(01):59.
[8]曹佳伟,李慧婷,徐玲玲,等.晚期肝癌患者行HAIC术后股动脉并发假性动脉瘤致骨筋膜室综合征的护理1例[J].介入放射学杂志,2024,33(04):459.
　CAO Jiawei,LI Huiting,XU Lingling,et al.Nursing care for osteofascial compartment syndrome caused by iatrogenic pseudoaneurysm in one patient with advanced liver cancer after receiving hepatic artery infusion chemotherapy[J].journal interventional radiology,2024,33(01):459.

备注/Memo

备注/Memo:
（收稿日期：2021-12-09）
（本文编辑：新　宇）
更新日期/Last Update: 2023-02-13